$32.55
+0.80 (+2.52%)
USD · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where APMD is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
13 interventional · 6 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Continuation Protocol for Obstructive Sleep Apnea (OSA)NCT06566820Number of Participants With Adverse Events (AES) and Serious Adverse Events (SAEs)Open-label · Other | Phase 3 | Enrolling by invitation | Drug: Aroxybutynin and Atomoxetine | OSA | 1,280 | 2026-06-30 | 2025-05-13 |
| Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)NCT05811247Change from Baseline in Apnea-Hypopnea Index (AHI)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: AD109, Placebo | OSA | 660 | 2025-05-07actual | 2025-11-21 |
| Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)NCT05813275Change from Baseline in Apnea-Hypopnea Index (AHI)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: AD109, Placebo | OSA | 646 | 2025-03-10actual | 2025-11-21 |
| Study That Tests AD109 in Patients Taking GLP-1 DrugsNCT06400615Primary Objective (Adverse Events)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: AD109 | OSA | 40 | 2024-12-26actual | 2025-02-19 |
| AD816 Crossover StudyNCT05793684Apnea-hypopnea index (AHI) 4%, AD816 vs. PlaceboRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Period A, Period B, Period C | OSA, Obstructive Sleep Apnea | 25 | 2023-11-09actual | 2023-11-15 |
| Trial of AD113 and Atomoxetine in OSA Patients With HypertensionNCT04905979Change in hypoxic burden (HB, total area under the respiratory event-related desaturation curve)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: AD113, Atomoxetine | Obstructive Sleep Apnea, Hypertension | 21 | 2023-01-31actual | 2023-08-21 |
| Parallel Arm Trial of AD109 and AD504 In Patients With OSANCT05071612results2026-08-12Change in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD109 Arms vs. PlaceboRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: AD109, AD504, Atomoxetine Hydrochloride, Placebo | OSA - Obstructive Sleep Apnea | 294 | 2022-07-20actual | 2026-08-12 |
| Study for Efficacy and Dose Escalation of AD313 + Atomoxetine (SEED)NCT05101122results2023-04-07Apnea-Hypopnea Index (AHI)4% Events Per HourNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 1/2 | Completed | Drug: Dosing 1: Atomoxetine, AD313 | Obstructive Sleep Apnea | 15 | 2022-04-18actual | 2023-04-07 |
| Crossover Trial of AD182 and AD504 in Obstructive Sleep ApneaNCT04645524Apnea-Hypopnea Index (AHI, average number of events for every hour of sleep)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: AD182, AD504, Placebo · Diagnostic test: Polysomnography | Obstructive Sleep Apnea | 15 | 2021-09-01actual | 2022-09-02 |
| AD109 Dose Finding in Mild to Moderate OSANCT04631107results2022-12-22Change in Hypoxic Burden (HB) Log Transformed - Log10HB[(%*Min)/h]Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: AD109 dose1- A, AD109 dose2- B, Placebo- C | Obstructive Sleep Apnea | 32 | 2021-05-31actual | 2022-12-22 |
| Crossover Trial of AD109 in Obstructive Sleep ApneaNCT04580394results2023-01-31Change in Hypoxic Burden (HB) Log10HB[(%*Min)/Hour]Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: AD109, Atomoxetine, R-oxybutynin, Placebo · Diagnostic test: Digit System Substitution Test | Obstructive Sleep Apnea | 60 | 2021-05-28actual | 2023-01-31 |
| Crossover Trial of AD036 in Obstructive Sleep ApneaNCT04445688results2023-08-21Apnea-Hypopnea IndexRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: AD036, Atomoxetine, Placebo | Obstructive Sleep Apnea | 62 | 2020-12-01actual | 2023-09-14 |
| Trial of AD036 in Obstructive Sleep ApneaNCT03845023results2023-01-17Apnea Hypopnea Index (AHI)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: AD036 Dose 1, AD036 Dose 2, AD036 Dose 3, Placebo | Obstructive Sleep Apnea | 140 | 2019-10-23actual | 2023-01-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19